Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort

Daniel P. Schauer, MD, MSc,* Heather Spencer Feigelson, PhD, MPH,† Corinna Koebnick, MSc, PhD,‡ Bette Caan, DrPH,§ Sheila Weinmann, PhD, MPH,¶ Anthony C. Leonard, PhD,∥ J. David Powers, MS,† Panduranga R. Yenumula, MD,§ and David E. Arterburn, MD, MPH**

Objective: To determine whether bariatric surgery is associated with a lower risk of cancer.

Background: Obesity is strongly associated with many types of cancer. Few studies have examined the relationship between bariatric surgery and cancer risk.

Methods: We conducted a retrospective cohort study of patients undergoing bariatric surgery between 2005 and 2012 with follow-up through 2014 using data from a large integrated health insurance and care delivery systems with 5 study sites. The study included 22,198 subjects who had bariatric surgery and 66,427 nonsurgical subjects matched on sex, age, study site, body mass index, and Elixhauser comorbidity index. Multivariable Cox proportional-hazards models were used to examine incident cancer up to 10 years after bariatric surgery compared to the matched nonsurgical patients.

Results: After a mean follow-up of 3.5 years, we identified 2543 incident cancers. Patients undergoing bariatric surgery had a 33% lower hazard of developing any cancer during follow-up [hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.60, 0.74, P < 0.001] compared with matched patients with severe obesity who did not undergo bariatric surgery, and results were even stronger when the outcome was restricted to obesity-associated cancers (HR 0.59, 95% CI 0.51, 0.69, P < 0.001). Among the obesity-associated cancers, the risk of postmenopausal breast cancer (HR 0.58, 95% CI 0.44, 0.77, P < 0.001), colon cancer (HR 0.59, 95% CI 0.36, 0.97, P = 0.04), endometrial cancer (HR 0.50, 95% CI 0.37, 0.67, P < 0.001), and pancreatic cancer (HR 0.46, 95% CI 0.22, 0.97, P = 0.04) was each significantly lower among those who had undergone bariatric surgery compared with matched nonsurgical patients.

Conclusions: In this large, multisite cohort of patients with severe obesity, bariatric surgery was associated with a lower risk of incident cancer, particularly obesity-associated cancers, such as postmenopausal breast cancer, endometrial cancer, and colon cancer. More research is needed to clarify the specific mechanisms through which bariatric surgery lowers cancer risk.

Keywords: bariatric surgery, cancer, obesity

(Ann Surg 2017;xxxx–xxx)
Bariatric surgery cases were identified using Current Procedural Terminology, 4th edition (CPT-4) and International Classification of Diseases, ninth revision (ICD-9) codes for surgery between January 1, 2005 and December 31, 2012. Subjects were 18 to 79 years of age at the time of surgery, and were excluded if they had a history of any cancer before surgery, identified by an ICD-9 diagnosis code or by a tumor registry entry, did not have 1 year of enrollment in the health plan before surgery extending to at least 6 months postsurgery, had a prior bariatric procedure, no documented BMI of at least 35 kg/m² within 1 year before surgery, or had a presurgery diagnosis of ascites or peptic ulcer disease (Fig. 1). Of the 33,378 potential surgical cases that were initially identified in the 5 sites, 22,198 patients who underwent bariatric surgery were included in the final analysis.

Control patients were identified from the same electronic health record databases and matched to surgical cases using a 2-phase matching process. Eligible controls had at least 1 BMI measurement ≥35 kg/m², and the sampling was weighted such that the pool of potential controls had a distribution of BMIs similar to that of the surgery cases. Potential controls were then matched to each surgical case using site, sex, and birth date within 1 year, allowing controls to be provisionally matched to multiple cases. The index date was the date of surgery for the bariatric surgery and the

FIGURE 1. Cohort consort for bariatric surgery patients and the matched nonsurgical controls.
corresponding date for the matched controls. We then excluded potential controls with a cancer before the index date, BMI <35, <6 months postindex date enrollment, and those with ascites or peptic ulcers. Remaining potential controls were further restricted to those with a BMI within 5% of a surgical case. Finally, up to 5 controls were selected for each case based on the smallest differences in Elixhauser comorbidity index score. The Elixhauser comorbidity index score is a method for quantifying patient comorbidity based upon administrative data. Controls with an Elixhauser difference of 3 or greater were removed from the matched set and returned to the pool of potential matches. At the end of phase 1, there were 265 cases that remained without a match. In the second phase of the matching process, the BMI matching window was extended to ±10% of the case, and the remaining potential controls were again matched with cases lacking 3 controls based on the smallest Elixhauser comorbidity index score difference. After this second matching process, 99.65% of cases had 3 matched controls, with 0.25% having 2 matched controls and 0.1% having 1 matched control. The second phase of the matching process yielded 2.85% of the final matches. After the second matching iteration, only 0.8% of matches had an Elixhauser score difference of 3 or greater, and only 62 bariatric cases remained without a match.

Outcomes
Incident cancers were identified from the tumor registries at each site. We included all types of cancers in our analysis and then separately considered obesity-associated cancers. Cancers were considered to be obesity-associated if they were 1 of the 14 types described by the International Agency for Research on Cancer (IARC) working group as having sufficient evidence for an association.2 These include esophageal adenocarcinoma, postmenopausal breast cancer and cancers of the kidney, colon, rectum, gastric cardia, liver, gallbladder, pancreas, ovary, corpus uteri, thyroid, multiple myeloma, and meningioma. We defined postmenopausal breast cancer as those diagnosed at age ≥55 years, consistent with previous studies using electronic data sources.25 In our primary analyses, we only considered cancers that occurred more than 6 months after the index date to minimize the impact of pre-existing cancers. In sensitivity analyses, we included all cancers after the index date.

Covariates
Covariates were identified using a combination of ICD-9 codes and CPT codes from inpatient and outpatient visit records, laboratory data, and pharmacy data in the year before the index date.

Follow-up Time
The follow-up time was calculated from the date of study inclusion (bariatric surgery or index date for matched controls) until the first occurrence of 1 of the following events: diagnosis of cancer, the end of health care coverage or a break of >92 days in health care coverage, death, or the end of follow-up on December 31, 2014.

Statistical Analysis
We calculated means, medians, and frequencies for variables to characterize the study sample. Subjects with a history of bariatric surgery were compared with the matched controls using standardized differences. Kaplan–Meier curves were generated for each outcome of interest. We estimated Cox proportional-hazards models to compare the development of any cancer, nonobesity-associated cancer, obesity-associated cancer, and individual obesity-associated cancers between the 2 groups. Matching was accounted for by using robust sandwich estimators. These estimators were chosen over estimators based on treating the matched sets as strata, because the sandwich estimators make more complete use of the data in the presence of covariates or when examining some subgroups. To assess the extent to which our results were sensitive to this choice of methods, we compared results from the 2 methods for our main outcomes. For each outcome, we created both unadjusted models and nonparsimonious models adjusted with the covariates that potentially impact cancer risk. We tested the assumption of constant proportional hazards over time by testing the surgery by time linear interaction. The alpha for all tests was a 2-tailed \( P = 0.05 \), unadjusted for multiple tests, and all analyses were performed using SAS v9.4 (Cary, NC).

RESULTS
In our final matched cohort, we had 22,211 bariatric surgical cases matched to 66,481 control subjects who did not receive surgery. Over 80% were female. Due to the matching process, surgery cases and controls were comparable on most demographic and clinical characteristics including the presence of diabetes and hypertension (Table 1). Subjects with a history of bariatric surgery were more likely to have several important cancer-related risk factors including a slightly higher BMI, higher prevalence of smoking, slightly greater use of hormone replacement therapy, and slightly higher baseline rates of nonalcoholic steatohepatitis. The use of screening mammograms was slightly higher amongst the control group in the year before the index date. The average follow-up time was longer in the bariatric surgery cases (47 months) than the controls (41 months; \( P < 0.001 \)). The bariatric surgery group developed 488 incident cases of cancer over 87,071 person-years of follow-up, whereas the nonsurgical group developed 2055 incident cases of cancer over 228,010 person-years of follow-up.

Kaplan–Meier curves show that the unadjusted rates of incident cancer differed across the bariatric cases and controls. The Kaplan–Meier plots for each group deviate early, and their diverging trajectories continue throughout the follow-up period (Fig. 2). Kaplan–Meier-estimated cancer-free survival at 3, 5, and 10 years, was 98.45%, 97.2%, and 94.11% for the bariatric surgery patients, and 97.34%, 95.56%, and 89.25% for the control patients, respectively.

In matched unadjusted and multivariable adjusted Cox proportional-hazards models, the proportional hazards assumption was met for all models. Patients undergoing bariatric surgery had a 33% lower hazard of developing any cancer during follow-up [hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.60, 0.74, \( P < 0.001 \)] than matched controls (Table 2). Results were similar when our outcomes were restricted to obesity associated cancers (HR 0.59, 95% CI 0.51, 0.69, \( P < 0.001 \)). Although there was no statistically significant interaction between the effect of bariatric surgery on cancer incidence by sex in these models, we had a priori planned to examine results with sex strata. Women who had bariatric surgery were associated with significantly fewer incident cancers (HR 0.64, 95% CI 0.57, 0.72, \( P < 0.001 \)), obesity-associated cancers (HR 0.58, 95% CI 0.49, 0.67, \( P < 0.001 \)), and cancers not obesity-associated (HR 0.74, 95% CI 0.62, 0.89, \( P = 0.001 \)) than in female control patients. For men, there were no statistically significant reductions in cancer risk for any cancer type, although there was a nonsignificant trend towards fewer obesity-associated cancers. The unadjusted and adjusted HRs were very similar for all analyses. All models accounted for the matching on age, sex, BMI, Elixhauser comorbidity index score, and study site, and the adjusted models were adjusted for race, diabetes, hyperlipidemia, hypertension, coronary artery disease, peripheral vascular disease, nonalcoholic steatohepatitis, a history of smoking, alcohol use, and use of hormone replacement therapy.
Of the obesity-related cancers, postmenopausal breast cancer (HR 0.58, 95% CI 0.44, 0.77, \(P < 0.001\)), colon cancer (HR 0.59, 95% CI 0.36, 0.97, \(P = 0.04\)), endometrial cancer (HR 0.50, 95% CI 0.37, 0.67, \(P < 0.001\)), and pancreatic cancer (HR 0.46, 95% CI 0.22, 0.97, \(P = 0.04\)) were all significantly lower after bariatric surgery compared with controls (Fig. 3). For esophageal adenocarcinoma, there were no cases amongst the bariatric surgery group and 16 cases in the control group (\(P = 0.02\)). Liver, gallbladder, multiple myeloma, ovarian, rectal, and thyroid cancer showed no statistically significant reduction in incidence after bariatric surgery compared with controls, although all of the HRs were less than 1.

For our primary analyses reported above, we excluded cancers occurring within 6 months after the index date. In sensitivity analyses, we eliminated this exclusion and included all cancers occurring after the index date. Our results were unchanged, but the association between bariatric surgery and lower cancer incidence was stronger (all cancers: HR 0.59, 95% CI 0.54, 0.66, \(P < 0.001\); obesity-associated cancers: HR 0.53, 95% CI 0.47, 0.61, \(P < 0.001\); cancers not associated with obesity: HR 0.67, 95% CI 0.59, 0.78, \(P < 0.001\)). In unadjusted models predicting each cancer outcome, the sandwich estimator method and the strata method produced HRs that differed by less than 10%, usually by less than 5%. The surgery-by-time linear interaction was nonsignificant in all models satisfying the assumption of constant proportional hazards over time.

**DISCUSSION**

Obesity is a significant risk factor for the development of many types of cancer. In this large multicenter cohort study, we found that bariatric surgery is associated with a lower long-term risk of cancer compared with carefully matched patients with severe obesity who did not get bariatric surgery. The reduction was greatest for...
FIGURE 2. (A) Kaplan–Meier-estimated cancer-free survival for all cancers; (B) obesity-associated cancers; and (C) cancers not associated with obesity. In panel A, there were 488 cancers in the bariatric surgery group and 2055 cancers in the matched controls. For the obesity-associated cancers in panel B, there were 246 cancers in the bariatric surgery group and 1185 in the matched controls. In panel C, there were 242 cancers not associated with obesity in the bariatric surgery group and 872 among the matched controls. The log-rank test had a P value of <0.001 for all three comparisons. The number at risk is the same in each panel because patients were censored at the first cancer regardless of the type.

TABLE 2. Hazard Ratios for the Risk of Cancer from Cox Regression Models

<table>
<thead>
<tr>
<th>Outcome</th>
<th>N</th>
<th>Unadjusted HR</th>
<th>95% CI</th>
<th>P</th>
<th>Adjusted HR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any cancer</td>
<td>87996</td>
<td>0.70</td>
<td>0.63–0.77</td>
<td>&lt;.001</td>
<td>0.67</td>
<td>0.60–0.74</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Obesity-associated cancer</td>
<td>87996</td>
<td>0.60</td>
<td>0.52–0.70</td>
<td>&lt;.001</td>
<td>0.59</td>
<td>0.51–0.69</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Cancer not associated with obesity</td>
<td>87996</td>
<td>0.83</td>
<td>0.71–0.96</td>
<td>0.01</td>
<td>0.77</td>
<td>0.66–0.89</td>
<td>0.001</td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any cancer</td>
<td>71341</td>
<td>0.66</td>
<td>0.50–0.75</td>
<td>&lt;.001</td>
<td>0.64</td>
<td>0.57–0.72</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Obesity-associated cancer</td>
<td>71341</td>
<td>0.58</td>
<td>0.50–0.68</td>
<td>&lt;.001</td>
<td>0.58</td>
<td>0.49–0.67</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Cancer not associated with obesity</td>
<td>71341</td>
<td>0.80</td>
<td>0.67–0.96</td>
<td>0.02</td>
<td>0.74</td>
<td>0.62–0.89</td>
<td>0.001</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any cancer</td>
<td>16655</td>
<td>0.85</td>
<td>0.68–1.07</td>
<td>0.17</td>
<td>0.79</td>
<td>0.63–1.02</td>
<td>0.054</td>
</tr>
<tr>
<td>Obesity-associated cancer</td>
<td>16655</td>
<td>0.71</td>
<td>0.47–1.07</td>
<td>0.1</td>
<td>0.7</td>
<td>0.46–1.07</td>
<td>0.1</td>
</tr>
<tr>
<td>Cancer not associated with obesity</td>
<td>16655</td>
<td>0.94</td>
<td>0.71–1.24</td>
<td>0.64</td>
<td>0.85</td>
<td>0.64–1.12</td>
<td>0.25</td>
</tr>
</tbody>
</table>

*All models accounted for matching on age, sex, BMI, Elixhauser comorbidity index score, and study site.
†All outcomes start at 6 months after the index date.
‡Models adjusted for race, diabetes, hyperlipidemia, hypertension, coronary artery disease, peripheral vascular disease, nonalcoholic steatohepatitis, a history of smoking, alcohol use, and use of hormone replacement therapy.
cancers that have been shown to be associated with obesity and persisted for the duration of 10-year follow-up in this study. Further, we found that some cancer types appeared to be reduced by bariatric surgery, whereas others did not. The differing rates of cancer reduction for the various obesity-related cancers is not surprising, given the multiple mechanisms by which obesity increases the risk of cancer. Reductions in cancer risk were strongest for postmenopausal breast and endometrial cancers. Both of these cancers are highly sensitive to estrogen levels and react rapidly to changes. Weight loss has been shown to reduce levels of circulating estrogen, thereby decreasing the risk of these cancers. Other obesity-associated cancers, such as thyroid cancer, may not be impacted as much by bariatric surgery due to the alternate mechanisms by which obesity increases their risk.

The risk of cancer was significantly lower among women, but not men, when the analysis was stratified. There are several potential reasons for this finding. Only women are at risk of developing postmenopausal breast and endometrial cancer, and these are the 2 most common obesity-associated cancers, with breast cancer being the most common cancer among women. Additionally, over 80% of the surgical cases were women. For men, prostate and lung cancer are the most common cancers, neither of which is associated with obesity.

Our results are consistent with several prior, smaller studies that examined the risk of cancer after bariatric surgery, including 2 with long-term follow-up. In the Utah Obesity Study of 6596 patients who had gastric bypass and were followed for a mean of 12.5 years, Adams and Hunt found that total cancer incidence was reduced (HR 0.76, 95% CI 0.65–0.89, P = 0.0006) and obesity-associated cancers were also reduced (HR 0.62, 95% CI 0.49–0.78, P < 0.0001). These HRs are slightly different than those reported here; however, Adams and Hunt only adjusted for age, sex, BMI, and did not account for differences in comorbidity across groups. The Swedish Obese Subjects (SOS) study included 10 bariatric cases and a well-defined comparison group of 2037 subjects that were matched on 18 clinical characteristics. The SOS study also found fewer cancers in the bariatric surgery cohort compared with the control patients (HR 0.67, 95% CI 0.53–0.85, P = 0.0009). Similarly to our study, the finding was significant in women, but not in men.

In our current study of gastric bypass and sleeve gastrectomy, which are the 2 main procedures performed in the United States, bariatric surgery was associated with a reduced risk of esophageal adenocarcinoma. A Swedish study including 34,437 bariatric surgery patients found no difference in esophageal adenocarcinoma incidence between bariatric surgery cases and the general obese population. However, this study did not match cases and controls, and, as in the SOS study, this study included bariatric procedures that are now outdated. These older procedures have different effects on weight loss and gastroesophageal reflux disease, which may explain the difference in our findings.

Finally, a study involving 15,095 bariatric surgery patients and 62,016 obese control patients identified from Swedish registries found an increased risk of colorectal cancer after bariatric surgery. This study has many of the same limitations as the other Swedish studies noted above, and importantly, did not distinguish between colon cancer and rectal cancer. It is likely that the impact of bariatric surgery on these 2 cancers is different, given their differing etiology, risk factors, and epigenetic and genetic profiles, as we found a reduction in the risk of colon cancer, but no reduction in the risk of rectal cancer.

Our study has several limitations. As in all observational studies, unmeasured differences may exist between the bariatric surgery patients and the control patients. While the matching process and control for covariates attempted to mitigate this, differences may persist, particularly in behavioral risk factors, such as diet and exercise. For example, we found that the control subjects in our study were more likely to get mammograms in the year before surgery, an example of a healthy behavior. However, with our rich resource of detailed data on longitudinal medical risk factors and cancer screening from the electronic medical record, we were able to match on an extensive list of covariates that were not previously considered in other studies of cancer outcomes after bariatric surgery. Another limitation is that we identified a history of smoking through ICD-9 codes, which may misclassify some individuals; however, this is unlikely to have a significant impact on our results, given that smoking is not a strong risk factor for most of the cancers in this study. Because our study is observational in nature, we cannot draw firm causal conclusions about the relationship between bariatric surgery and incident cancer. However, many of the elements of causality are met, including the large effect size, the consistency of the associations across multiple observational studies, the plausibility of the mechanism of effect (particularly for obesity-associated cancers), and the temporality demonstrated in this long-term follow-up study. A limitation of this study is that the average follow-up was less than 4 years. Given the natural history of many cancers, this may lead to underestimation of the association between bariatric surgery and cancer as the effect may not be seen for several years. However, the hazards remained proportional throughout follow-up, meaning that the association between bariatric surgery and cancer risk did not change over time. Our study also has many strengths. The large sample size, comprehensive data sources, long term follow-up, and matching methods all contribute to the strength of the results.
CONCLUSIONS

In this carefully matched retrospective cohort study, we have demonstrated that bariatric surgery is associated with a lower the risk of obesity-associated cancers, especially postmenopausal breast, endometrial, and colon cancer. We found no significant association between bariatric surgery and cancer risk among men. Promoting intentional weight loss, especially through the use of bariatric surgery, may greatly reduce the risk of cancer amongst patients with severe obesity.

REFERENCES